… Mitoxantrone plus prednisone reduces pain and improves the quality of … prostate cancer,
but it does not improve survival. We compared such treatment with docetaxel plus prednisone in …

… the cost effectiveness of docetaxel and other new treatments for men with prostate cancer.
In conclusion, docetaxel administered every 3 weeks with prednisone remains the preferred …

… One of the trials, TAX-327 (Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone
for Advanced Prostate Cancer), included a weekly docetaxel schedule in which the median …

… Prostate cancer is the most frequent cancer and the second most common cause of cancer
… (B) Overall survival of patients receiving docetaxel/estramustine versus docetaxel alone after …

… Docetaxel-based chemotherapy has been shown to be … prostate cancer (HRPC). This
study was undertaken to assess the feasibility of docetaxel in combination with prednisolone in …

… have limited therapeutic options, with docetaxel chemotherapy being the only approved …
In a phase III trial of docetaxel and prednisone given every 3 weeks, confirmed prostate-…

Background Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen
receptor translocation and signalling. The aim of this study is to assess the efficacy of …

… of adding bevacizumab to standard docetaxel and prednisone therapy administered every 3
… probability to receive docetaxel (D:75 mg/m 2 IV over 1 hour q 21 days), plus prednisone (P) …

… of metastatic castration-resistant prostate cancer has been docetaxel with prednisone. … in
human prostate cancer. In a randomised phase 2 study of docetaxel and prednisone with or …

… Here, we compare outcomes of men with metastatic castrate-resistant prostate cancer (mCRPC)
treated with docetaxel and prednisone in routine practice and in clinical trials. …